ADP-dependent glucokinase controls metabolic fitness in prostate cancer progressionHang Xu, Jianzhong Ai, Xingyu Xiong et al.|Military Medical Research|2023Cited by 17
CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancerXiaonan Zheng, Qiang Wei, Hang Xu et al.|Computers in Biology and Medicine|2022Cited by 11
<p>The accumulation of metabolic syndrome components is associated with higher risk of positive surgical margin among patients with localized prostate cancer after radical prostatectomy</p>Xiaonan Zheng, Qiang Wei, Kun Jin et al.|OncoTargets and Therapy|2019Cited by 6
A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).Feng Wen, Yali Shen, Mengni Zhang et al.|Journal of Clinical Oncology|2025Cited by 3
Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02).Feng Wen, Yali Shen, Ping Tan et al.|Journal of Clinical Oncology|2025Cited by 2